Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, John Rose, James P. Sheridan et al.|The Lancet Neurology|2010Cited by 300
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gilmore O’Neill, Gavin Giovannoni et al.|The Lancet|2013Cited by 287
Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindredsMargaret E. Brousseau, Jessie Gu, Ernst J. Schaefer et al.|Journal of Lipid Research|2000Cited by 130
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Gilmore O’Neill, Ralf Gold et al.|The Lancet Neurology|2014Cited by 94